EGFR co-targeting and nanotechnology offer new triple-negative breast cancer therapies

EGFR co-targeting and nanotechnology offer new triple-negative breast cancer therapies

Triple-negative breast cancer (TNBC) remains one of the most challenging forms of breast cancer to treat because it lacks the estrogen, progesterone and HER2 receptors that enable targeted treatment in other breast cancer subtypes.

Rethinking Triple-Negative Breast Cancer Treatment Through EGFR Co-Targeting and Nanotechnology

Triple-negative breast cancer (TNBC) remains one of the most challenging forms of breast cancer to treat because it lacks the estrogen, progesterone and HER2 receptors that enable targeted treatment in other breast cancer subtypes. A review published in Genes & Diseases examines how targeting the epidermal growth factor receptor (EGFR) alongside other molecular targets, supported by nanocarrier-based delivery, could offer new possibilities for m…

Small Triple-Negative Breast Tumors Blur the Line Between Stage I and Stage

Triple-negative breast cancer has long been one of the most feared diagnoses in oncology. Lacking the estrogen, progesterone, and HER2 receptors that anchor most modern breast cancer therapies, it behaves aggressively, recurs early, and offers few targeted options. Yet a new retrospective study suggests that for the smallest, node-negative tumors, the sharp stage boundaries that […]